Evidence map›Paper›PMID 32348959›Full record

ArticleEndocrine-related cancer2020

Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia.

Fady Hannah-Shmouni, Annabel Berthon, Fabio R Faucz, Juan Medina Briceno, Andrea Gutierrez Maria, Andrew Demidowich, Mirko Peitzsch, Jimmy Masjkur, Fidéline Bonnet-Serrano, Anna Vaczlavik and 4 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Endocrine-related cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 3 countries.

Fady Hannah-ShmouniSection on Endocrinology and Genetics, TheEunice Kennedy ShriverInstitute of Child Health and Human Development National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-6829-6205
Annabel BerthonSection on Endocrinology and Genetics, TheEunice Kennedy ShriverInstitute of Child Health and Human Development National Institutes of Health, Bethesda, Maryland, USA.
Fabio R FauczSection on Endocrinology and Genetics, TheEunice Kennedy ShriverInstitute of Child Health and Human Development National Institutes of Health, Bethesda, Maryland, USA.
Juan Medina BricenoSection on Endocrinology and Genetics, TheEunice Kennedy ShriverInstitute of Child Health and Human Development National Institutes of Health, Bethesda, Maryland, USA.
Andrea Gutierrez MariaSection on Endocrinology and Genetics, TheEunice Kennedy ShriverInstitute of Child Health and Human Development National Institutes of Health, Bethesda, Maryland, USA.
Andrew DemidowichSection on Endocrinology and Genetics, TheEunice Kennedy ShriverInstitute of Child Health and Human Development National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-5925-1117
Mirko PeitzschInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, TechnischeUniversität, Dresden, Germany.
Jimmy MasjkurDepartment of Medicine III, University Hospital Carl Gustav Carus, TechnischeUniversität, Dresden, Germany.
Fidéline Bonnet-SerranoDepartments of Endocrinology & Hormonal Biology, Cochin Hospital, INSERM U1016, CNRS 8104, Institut Cochin, Paris Descartes University, Paris, France.
Anna VaczlavikDepartments of Endocrinology & Hormonal Biology, Cochin Hospital, INSERM U1016, CNRS 8104, Institut Cochin, Paris Descartes University, Paris, France.
Jérôme BertheratDepartments of Endocrinology & Hormonal Biology, Cochin Hospital, INSERM U1016, CNRS 8104, Institut Cochin, Paris Descartes University, Paris, France.
Martin ReinckeMedizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany.
Graeme EisenhoferInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, TechnischeUniversität, Dresden, Germany.
Constantine A StratakisSection on Endocrinology and Genetics, TheEunice Kennedy ShriverInstitute of Child Health and Human Development National Institutes of Health, Bethesda, Maryland, USA.
National Institutes of Health · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USUniversity Hospital Carl Gustav Carus · DECentre National de la Recherche Scientifique · FRHôpital Cochin · FRInstitut Cochin · FRLudwig-Maximilians-Universität München · DETU Dresden · DE

Funding

Intramural NIH HHS Z99 HD999999
6 · The paper itself

Abstract

Biochemical characterization of primary bilateral macronodular adrenocortical hyperplasia (PBMAH) by distinct plasma steroid profiles and its putative correlation to disease has not been previously studied. LC-MS/MS-based steroid profiling of 16 plasma steroids was applied to 36 subjects (22 females, 14 males) with PBMAH, 19 subjects (16 females, 3 males) with other forms of adrenal Cushing's syndrome (ACS), and an age and sex-matched control group. Germline ARMC5 sequencing was performed in all PBMAH cases. Compared to controls, PBMAH showed increased plasma 11-deoxycortisol, corticosterone, 11-deoxycorticosterone, 18-hydroxycortisol, and aldosterone, but lower progesterone, DHEA, and DHEA-S with distinct differences in subjects with and without pathogenic variants in ARMC5. Steroids that showed isolated differences included cortisol and 18-oxocortisol with higher (P < 0.05) concentrations in ACS than in controls and aldosterone with higher concentrations in PBMAH when compared to controls. Larger differences in PBMAH than with ACS were most clear for corticosterone, but there were also trends in this direction for 18-hydroxycortisol and aldosterone. Logistic regression analysis indicated four steroids - DHEA, 11-deoxycortisol, 18-oxocortisol, and corticosterone - with the most power for distinguishing the groups. Discriminant analyses with step-wise variable selection indicated correct classification of 95.2% of all subjects of the four groups using a panel of nine steroids; correct classification of subjects with and without germline variants in ARMC5 was achieved in 91.7% of subjects with PBMAH. Subjects with PBMAH show distinctive plasma steroid profiles that may offer a supplementary single-test alternative for screening purposes.

Indexed as

Adrenal Gland NeoplasmsCross-Sectional StudiesCushing SyndromeFemaleHumansMaleMiddle AgedSteroidsTandem Mass SpectrometrySteroidsARMC5cortisolCushing's syndromemass-spectrometryPBMAHsteroids

Identifiers

PMID32348959
PMCPMC7354003
OpenAlexW3019360855

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.